• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    3/20/23 4:22:21 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email
    SC 13D/A 1 d10603587_13d-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 3)*

     

     

    Absci Corporation
    (Name of Issuer)

     

     

    Common Stock, $0.0001 par value
    (Title of Class of Securities)

     

     

    00091E109
    (CUSIP Number)

     

     

    Eli Casdin

    Casdin Capital, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York

    Telephone Number (212) 897-5438

    (Name, Address and Telephone Number of Person Authorized to Receive

    Notices and Communications)

     

     

    March 16, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [  ].

     

    _______________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Capital, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      5,533,260  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      5,533,260  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      5,533,260  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      6.0%  

     

    14. TYPE OF REPORTING PERSON  
         
      IA  

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners Master Fund, L.P.  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      WC  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      4,560,000  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      4,560,000  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      4,560,000  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.9%  

     

    14. TYPE OF REPORTING PERSON  
         
      PN  

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Casdin Partners GP, LLC  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      4,560,000  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      4,560,000  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      4,560,000  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      4.9%  

     

    14. TYPE OF REPORTING PERSON  
         
      OO  

     

     


    CUSIP No.
    00091E109    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Eli Casdin  

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
        (a)   [_]
        (b) [_]

     

    3. SEC USE ONLY  
         
         

     

    4. SOURCE OF FUNDS  
         
      AF  

     

    5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)   [_]

     

    6. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7. SOLE VOTING POWER  
         
      0  

     

    8. SHARED VOTING POWER  
         
      5,533,260  

     

    9. SOLE DISPOSITIVE POWER
         
      0  

     

    10. SHARED DISPOSITIVE POWER  
         
      5,533,260  

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
      5,533,260  

     

    12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   [_]

     

    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
         
      6.0%  

     

    14. TYPE OF REPORTING PERSON  
         
      IN  

     

     

     

    CUSIP No. 00091E109    

     

    Item 1. Security and Issuer.  

     

      The name of the issuer is Absci Corporation, a Delaware corporation (the "Issuer").  The address of the Issuer's principal executive offices is 18105 SE Mill Plain Blvd, Vancouver, Washington, 98683.  This Schedule 13D relates to the Issuer's Common Stock, $0.0001 par value (the "Shares").  
         
         

     

    Item 2. Identity and Background.  

     

      (a), (f) This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company (“Casdin”), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the “Fund”), Casdin Partners GP, LLC, a Delaware limited liability company (the “GP”) and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").    
           
      (b) The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.  
           
      (c) Eli Casdin is the managing member of Casdin and the GP.  The principal business of Casdin is serving as an investment adviser to its clients.  The principal business of the GP is serving as the general partner to certain private funds.  Casdin is the investment manager to the Fund and the GP is the general partner of the Fund.  The principal business of the Fund is purchasing, holding and selling securities for investment purposes.  
           
      (d), (e) During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.  The Reporting Persons disclaim membership in a group.    
         

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.  
         
      The funds for the purchase of the Shares came from the working capital of private investment funds managed by Casdin, including the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion.  No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.      
         

     

    Item 4. Purpose of Transaction.  
         
     

    The Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934.

     

    On July 8, 2022, Eli Casdin, a director of the Issuer, notified the Issuer of his decision to step down from the Board of Directors of the Issuer, effective July 11, 2022. Mr. Casdin’s decision was not the result of any disagreement with the Issuer on matters related to the Issuer’s operations, policies or practices.

     

    The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own.

     

    The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value.

     

    The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.

     
         

     

     

     

    Item 5. Interest in Securities of the Issuer.  
         
      (a) - (e)

    As of the date hereof, Casdin and Eli Casdin may be deemed to be the beneficial owners of 5,533,260 Shares, constituting 6.0% of the Shares, based upon 92,394,909* Shares outstanding.

     

    Casdin and Eli Casdin have the sole power to vote or direct the vote of 0 Shares; have the shared power to vote or direct the vote of 5,533,260 Shares; have the sole power to dispose or direct the disposition of 0 Shares; and have the shared power to dispose or direct the disposition of 5,533,260 Shares.

     

    As of the date hereof, the Fund and the GP may be deemed to be the beneficial owners of 4,560,000 Shares, constituting 4.9% of the Shares, based upon 92,394,909* Shares outstanding.

     

    The Fund and the GP have the sole power to vote or direct the vote of 0 Shares; have the shared power to vote or direct the vote of 4,560,000 Shares; have the sole power to dispose or direct the disposition of 0 Shares; and have the shared power to dispose or direct the disposition of 4,560,000 Shares.

     

    The transactions by the Reporting Persons in the Shares during the past sixty days are set forth in Exhibit B. All such transactions were carried out in open market transactions.

     

    All of the Shares are beneficially owned by the Fund and another private investment fund managed by Casdin.

     

    The Fund and the GP no longer own more than 5% of the total outstanding Shares. Consequently, this is the final amendment to the Schedule 13D and constitutes an “exit filing” for the Fund and the GP.

     

    *This outstanding Shares figure reflects the number of outstanding Shares as reported in the 10-Q filed by the Issuer on November 9, 2022.

     
           

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.  
         
      Not Applicable  
         

     

    Item 7. Material to be Filed as Exhibits.  

     

     

    Exhibit A: Joint Filing Agreement

         

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      March 20, 2023
      (Date)
       
       
      Casdin Capital, LLC*
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners Master Fund, L.P.
      By: Casdin Partners GP, LLC, its general partner
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners GP, LLC*
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
      Eli Casdin

     

    * This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 10001).

     

     

    Exhibit A

     

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13D amendment, dated March 20, 2023, relating to the Common Stock, $0.0001 par value of Absci Corporation shall be filed on behalf of the undersigned.

     

      March 20, 2023
      (Date)
       
       
      Casdin Capital, LLC
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners Master Fund, L.P.
      By: Casdin Partners GP, LLC, its general partner
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      Casdin Partners GP, LLC
       
      By: /s/ Eli Casdin
      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin
      Eli Casdin

     

     

     

    Exhibit B

     

     

    Schedule of Transactions in Shares

     

     

    Date of Transaction Title of Class Number of Shares Acquired Number of Shares Disposed

    Price Per Share

             
    2/13/2023 Common Stock, $0.0001 par value   40,000 $2.6330
    2/14/2023 Common Stock, $0.0001 par value   55,000 $2.6656
    2/14/2023 Common Stock, $0.0001 par value   5,000 $2.6278
    2/15/2023 Common Stock, $0.0001 par value   25,000 $2.7269
    2/15/2023 Common Stock, $0.0001 par value   5,000 $2.7419
    2/16/2023 Common Stock, $0.0001 par value   40,000 $2.7032
    2/17/2023 Common Stock, $0.0001 par value   25,000 $2.6436
    2/21/2023 Common Stock, $0.0001 par value   25,000 $2.4634
    2/21/2023 Common Stock, $0.0001 par value   45,000 $2.3946
    2/22/2023 Common Stock, $0.0001 par value   100,000 $2.4315
    2/23/2023 Common Stock, $0.0001 par value   50,000 $2.3463
    2/23/2023 Common Stock, $0.0001 par value   5,000 $2.3200
    2/24/2023 Common Stock, $0.0001 par value   20,000 $2.2066
    2/24/2023 Common Stock, $0.0001 par value   9,881 $2.2251
    2/27/2023 Common Stock, $0.0001 par value   5,000 $2.1946
    2/28/2023 Common Stock, $0.0001 par value   30,119 $2.1281
    3/1/2023 Common Stock, $0.0001 par value   20,000 $2.0120
    3/2/2023 Common Stock, $0.0001 par value   155,000 $2.1279
    3/2/2023 Common Stock, $0.0001 par value   35,000 $2.1781
    3/2/2023 Common Stock, $0.0001 par value   10,000 $2.1481
    3/3/2023 Common Stock, $0.0001 par value   30,000 $2.1759
    3/6/2023 Common Stock, $0.0001 par value   17,000 $2.1638
    3/6/2023 Common Stock, $0.0001 par value   3,000 $2.1915
    3/6/2023 Common Stock, $0.0001 par value   5,000 $2.0740
    3/7/2023 Common Stock, $0.0001 par value   48,500 $2.1427
    3/7/2023 Common Stock, $0.0001 par value   1,500 $2.1377
    3/8/2023 Common Stock, $0.0001 par value   30,000 $2.0350
    3/8/2023 Common Stock, $0.0001 par value   25,000 $1.9839
    3/10/2023 Common Stock, $0.0001 par value   15,000 $1.9345
    3/13/2023 Common Stock, $0.0001 par value   10,000 $1.7845
    3/14/2023 Common Stock, $0.0001 par value   15,000 $1.7676
    3/15/2023 Common Stock, $0.0001 par value   15,000 $1.7151
    3/16/2023 Common Stock, $0.0001 par value   10,000 $1.6822
    3/17/2023 Common Stock, $0.0001 par value   10,000 $1.5882

     

     

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    6/4/2026$12.00Outperform
    Leerink Partners
    5/28/2026$9.00Buy
    BTIG Research
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    10/2/2025Overweight
    Analyst
    7/3/2025$7.00Overweight
    Morgan Stanley
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    More analyst ratings

    $ABSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    7/6/26 4:06:13 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Mcclain Sean covered exercise/tax liability with 59,896 shares, decreasing direct ownership by 0.69% to 8,655,555 units (SEC Form 4) (for tax liability)

    4 - Absci Corp (0001672688) (Issuer)

    6/26/26 4:21:34 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: Director Szela Mary T was granted 8,400 shares (SEC Form 4)

    4/A - Absci Corp (0001672688) (Issuer)

    6/15/26 8:40:31 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

    Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

    7/15/26 8:45:00 AM ET
    $ABCL
    $ABSI
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Semiconductors

    Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

    VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. T

    7/14/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel

    A wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /CNW/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the

    7/6/26 8:45:00 AM ET
    $ABSI
    $AZN
    $CERT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Software: Prepackaged Software

    $ABSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Absci Corporation with a new price target

    Leerink Partners initiated coverage of Absci Corporation with a rating of Outperform and set a new price target of $12.00

    6/4/26 8:44:36 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BTIG Research initiated coverage on Absci Corporation with a new price target

    BTIG Research initiated coverage of Absci Corporation with a rating of Buy and set a new price target of $9.00

    5/28/26 8:55:01 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    SEC Filings

    View All

    SEC Form 8-K filed by Absci Corporation

    8-K - Absci Corp (0001672688) (Filer)

    6/24/26 4:31:58 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 424B5 filed by Absci Corporation

    424B5 - Absci Corp (0001672688) (Filer)

    6/24/26 4:30:10 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Absci Corp (0001672688) (Filer)

    6/24/26 6:32:11 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    7/6/26 4:06:13 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Pangalos Menelas N bought $200,748 worth of shares (37,453 units at $5.36), increasing direct ownership by 19% to 232,308 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    5/13/26 4:05:17 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/16/26 4:17:22 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Leadership Updates

    Live Leadership Updates

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

    MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ:ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, "Partnering to Power the New Era of Drug Discovery," will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr. Debanjana Chatterjee and Dr. Danya Ben-Hail, the panel will explore how the convergence of high-performance compute, native biological knowledge representations, and generative AI can dismantle longstanding barriers in drug discover

    6/12/26 9:00:00 AM ET
    $ABSI
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Financials

    Live finance-specific insights

    View All

    As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

    Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicine's biggest frontiers: GLP-1 metabolic health and infectious disease.AUSTIN, Texas, July 15, 2026 /CNW/ -- Equity Insider News Commentary - Artificial intelligence has moved from the edges of drug discovery to its center. The biggest pharmaceutical companies in the world are now racing to design molecules with machine learning rather than trial and error, and the market has begun to reward the names building the infrastructure underneath that shift. MindWalk H

    7/15/26 8:45:00 AM ET
    $ABCL
    $ABSI
    $HYFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Semiconductors

    Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

    VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. T

    7/14/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

    Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the

    5/7/26 4:05:00 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Absci Corporation

    SC 13G - Absci Corp (0001672688) (Subject)

    11/14/24 4:02:50 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Absci Corporation

    SC 13G/A - Absci Corp (0001672688) (Subject)

    11/12/24 9:50:12 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Absci Corporation (Amendment)

    SC 13D/A - Absci Corp (0001672688) (Subject)

    3/5/24 5:15:30 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care